

## **Dear Esteemed Members of the ESGO Council,**

I am writing to express my deep commitment and enthusiasm for the opportunity to serve as a non-European member on the ESGO Council. As a dedicated member of the European Society of Gynaecological Oncology (ESGO) hailing from India, I am honoured to participate in this historic moment when ESGO opens its doors to global perspectives. I currently serve as an Associate Professor and surgeon at the prestigious Tata Memorial Centre in India, a hub for excellence in cancer care and research in Asia. This role has afforded me a unique vantage point to witness the challenges and opportunities in delivering care to diverse populations across countries.

My vision is clear: to spearhead innovation and research initiatives that make optimum cancer care accessible to the majority of nations worldwide. It aligns perfectly with ESGO's mission to advance the science and practice of gynaecological oncology on a global scale.

In my tenure on the ESGO Council, I pledge to prioritize the following:

1.*Equity in Cancer Care*: I am deeply committed to ensuring that every gynaecological cancer patient, regardless of their geographical location or socio-economic background, receives the best possible care. My motto, "Optimum and affordable care to every gynaecological cancer patient irrespective of regional differences and nationality," encapsulates this commitment.

2.*Innovation and Research*: I will champion initiatives that foster breakthroughs in gynaecological oncology. This includes promoting research on cutting-edge technologies, novel molecules, and advanced surgical techniques that can enhance patient outcomes and make cancer care more affordable.

3.*Global Collaboration*: I will actively seek collaborations with international organizations, experts, and institutions to facilitate knowledge exchange and harmonize best practices in gynaecological oncology

*4.Education and Training:* I recognize the importance of capacity building and will work to create educational programs that empower healthcare professionals in underprivileged regions, ultimately improving the quality of care they can offer to their patients.

I humbly request your support and vote for my candidacy in the ESGO Council Elections 2024. Together, we can shape a future where every gynaecological cancer patient receives the care they deserve, regardless of where they live. Thank you for considering my candidacy, and I look forward to the opportunity to serve our esteemed organization and its noble mission.

Sincerely,

Biswajit Dash

**Dr.Biswajit Dash ,M.D ,M.Ch**

*Associate Professor and surgeon,*

*Div. of Gynaecological Oncology,*

*Dept of Surgical Oncology,*

*Tata Memorial Centre,*

*Mumbai,*

*India*

**Curriculum Vitae**



- **Dr Biswajit Dash, M.D (O&G), M.Ch.(Gynec Oncology )**

*Associate Professor and Consultant surgeon,*

*Div of Gynecological Oncology , Dept of Surgical Oncology*

*Tata Memorial Centre, Mumbai – 400012, INDIA*

- *Present position (Elected): Executive Committee Member(2022-2024), The Association of Gynaecologic Oncologists of India (AGOI*

*email : dbiswajit\_dr@yahoo.com*

*Mobile :+91-7978831835,8895331662*

*D.O.B – 28/04/1980*

- **Affiliations** : ESGO, FOGSI, AGOI, IMA

- **Awards** : YGOG Award (AGOI ,INDIA 2012)

ASGO sponsored Young doctor (SEOUL 2014)

ACORD Scholar (SYDNEY 2018)

- **Publications** :

1,Proximal-type epithelioid sarcoma of vulva - Case series of a rare tumor.Dash B, Rekhi B, Shylasree TS, Maheshwari A, Bajpai J.

Gynecol Oncol Rep. 2022 Jan 6;39:100921. doi:  
10.1016/j.gore.2022.100921. eCollection 2022 Feb.

PMID: 35059488

2.Dash, B., Shylasree, T.S., Rekhi, B. *et al.* Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center. *Indian J Surg Oncol* (2023).

<https://doi.org/10.1007/s13193-023-01775-z>

3.Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.

Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayasamy Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S; *CovidSurg Gynecological Cancer Collaborators*.

*Am J Obstet Gynecol*. 2022 Nov;227(5):735.e1-735.e25. doi:

10.1016/j.ajog.2022.06.052. Epub 2022 Jun 30.

4.Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.  
COVIDSurg Collaborative.

*Lancet Oncol*. 2021 Nov;22(11):1507-1517. doi: 10.1016/S1470-2045(21)00493-9. Epub 2021 Oct 5.

PMID: 34624250 Free PMC article. Clinical Trial.

- **SPECIAL INTERESTS:** MIS in gynaecological oncology, fertility preservation in oncology, cytoreductive surgery and HIPEC ,Low grade serous cancers of ovary, Germ cell tumours

